State Street’s MoonLake Immunotherapeutics MLTX Stock Holding History

State Street’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.05M	Buy	56,490 +5,517	+11%	+$91.4K	﹤0.01%	3477
2025 Q4	$672K	Sell	50,973 -1,913	-4%	-$22.6K	﹤0.01%	3609
2025 Q3	$379K	Sell	52,886 -11,678	-18%	-$609K	﹤0.01%	3724
2025 Q2	$3.05M	Sell	64,564 -28,833	-31%	-$1.17M	﹤0.01%	3157
2025 Q1	$3.65M	Buy	93,397 +1,852	+2%	+$79.8K	﹤0.01%	3005
2024 Q4	$4.96M	Buy	91,545 +3,908	+4%	+$200K	﹤0.01%	2985
2024 Q3	$4.42M	Buy	87,637 +42,980	+96%	+$2.01M	﹤0.01%	3023
2024 Q2	$1.96M	Sell	44,657 -704	-2%	-$29.8K	﹤0.01%	3325
2024 Q1	$2.28M	Buy	45,361 +15,020	+50%	+$815K	﹤0.01%	3237
2023 Q4	$1.83M	Buy	30,341 +9,541	+46%	+$492K	﹤0.01%	3340
2023 Q3	$1.19M	Buy	+20,800	New	+$1.15M	﹤0.01%	3486

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street's MLTX Position: Q1 2026 in Review

State Street increased its MoonLake Immunotherapeutics (MLTX) stake by 11% in Q1 2026, buying an estimated $91.4K and bringing the position to 56,490 shares worth $1.05M. The position accounts for ﹤0.01% of the portfolio, ranked #3477.

State Street first reported a position in MLTX in Q3 2023 and has held it in 11 quarters since. The position peaked at $4.96M in Q4 2024. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

State Street held 56,490 shares of MoonLake Immunotherapeutics worth $1.05M as of Q1 2026.
State Street bought 5,517 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $91.4K.
MoonLake Immunotherapeutics made up ﹤0.01% of State Street's portfolio in Q1 2026, its #3477 holding.
State Street first reported a position in MoonLake Immunotherapeutics in Q3 2023 and has held it in 11 quarters since.
State Street's MoonLake Immunotherapeutics position peaked at $4.96M in Q4 2024.
147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.